An earlier clinical trial found a higher number of acute myocardial infarction events in those administered HepB-CpG vaccine versus those administered the HepB-alum vaccine.
Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.
CDI is the leading cause of diarrhea in hospitalized patients.
PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.
Because there is an inflammatory component to Down syndrome regression disorder, it may potentially be reversible with immunotherapy.
Brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% is a generic equivalent to AbbVie’s Combigan, which reduces eye pressure in patients with ocular hypertension.
V116 is a novel 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia.
Blue Earth Therapeutics will begin an open-label, multicenter trial to evaluate a next-generation radiopharmaceutical for metastatic castration-resistant prostate cancer.
Ravulizumab-cwvz (Ultomiris) produced statistically significant improvements in measures of functional activity, muscle strength, and quality of life in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.
Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.
Study finds that health care providers need to reinforce the importance of annual mammograms among patients who survived breast cancer.
Recent studies that indicated the efficacy of IVIG in patients with myelin oligodendrocyte glycoprotein antibody-associated disease used pediatric cohorts, with few evaluations of the treatment approach in adults.
Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Vaxneuvance was previously granted FDA Priority Review and Breakthrough Therapy designation for the prevention of invasive pneumococcal disease.
Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.
Lowering salt intake was not found to reduce visits to the emergency department, however, there were improvements in quality of life.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Evelyn Handel, PharmD, BCPS, BCOP, director of drugs & biologics programs at the National Comprehensive Cancer Network, presented the keynote address, which was developed in collaboration with Emily Mackler, PharmD, BCOP, of the Michigan Oncology Quality Consortium in Ann Arbor.
This topic was presented by Jolynn K. Sessions, PharmD, BCOP, at the 2019 Directions in Oncology Pharmacy™ conference.
The 2019 Directions in Oncology Pharmacy™ conference included a session covering relapsed and refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL).
The second session at the 2019 Directions in Oncology Pharmacy™ conference discussed emerging clinical options for patients who have chronic lymphocytic leukemia (CLL), with a special emphasis on the pharmacist’s role.
This year, particular clinical advancements in breast, lung, and ovarian cancers were heavily represented among the late-breaking abstract presentations.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
